Douglas W. McMillin - Concepedia

Author

Douglas W. McMillin

Dana-Farber Cancer Institute

Also Known As

D McMillin, D. W. McMillin, Douglas McMillin, Douglas W McMillin, Douglas W. McMillin, Douglas. W McMillin

150

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Harvard University Massachusetts Eye and Ear Infirmary VA Boston Healthcare System Aristotle University of Thessaloniki

About

Douglas W. McMillin is an author at Dana-Farber Cancer Institute specializing in medicine, cell biology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	715
2	Health Sciences	2	2	181
3	Natural Sciences	1	1	55
4	Biochemistry	1	1	55
5	Blood Transplantation	1	1	24

Douglas W. McMillin

Publications

2.8K

Citations

H-Index

Page 1

	Year	Citations
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor Nicholas Kwiatkowski, Tinghu Zhang, Peter B. Rahl, Nature	2014	882
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity Douglas W. McMillin, Jake Delmore, Ellen Weisberg, Nature Medicine Drug ActivityTumor BiologyDrug TargetingMedicineTheranostics	2010	313
VLA-5 is expressed by mouse and human long-term repopulating hematopoietic cells and mediates adhesion to extracellular matrix protein fibronectin. Jocelyn Loo, Xiang Xiao, Douglas W. McMillin, Journal of Clinical Investigation Cell AdhesionImmunologyBlood CellMatrix Protein FibronectinAntigen Processing	1998	162
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia Xavier Leleu, Xiaoying Jia, Judith Runnels, Blood	2007	141
Antitumor Effects of the Proteasome Inhibitor Bortezomib in Medullary and Anaplastic Thyroid Carcinoma Cells in Vitro Constantine S. Mitsiades, Douglas W. McMillin, Vassiliki Kotoula, The Journal of Clinical Endocrinology & Metabolism	2006	127
Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 Douglas W. McMillin, Melissa Ooi, Jake Delmore, Cancer Research	2009	122
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl) Klaus Podar, Marc S. Raab, Jing Zhang, Blood	2006	119
Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells Ellen Weisberg, Andrew L. Kung, Renee D. Wright, Molecular Cancer Therapeutics	2007	77
Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma David Cervi, Melissa Ooi, Saifun Nahar, Haematologica	2011	73
Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells Ellen Weisberg, Renee D. Wright, Douglas W. McMillin, Molecular Cancer Therapeutics	2008	73

Page 1